Patricia Inácio, PhD, science writer —

Enrollment for a Phase 1b basket clinical trial of povetacicept (ALPN-303), an experimental anti-inflammatory therapy, for adults with cold agglutinin disease (CAD) and other autoimmune cytopenias is expected to start in the coming months. That’s according to a corporate update from the treatment’s developer, Alpine Immune Sciences. Basket…

Enrollment is underway in a Phase 3 clinical trial testing the investigational therapy pegcetacoplan in adults with primary cold agglutinin disease (CAD), according to a corporate update from the treatment’s developer, Apellis Pharmaceuticals. The trial, called CASCADE (NCT05096403), is enrolling up to 57 patients, 18…

Signs of cold agglutinin disease (CAD) — later found to have been triggered by a previous COVID-19 infection — were detected during heart surgery in a man in Turkey, a case study showed. The case adds to several others reporting developing CAD following COVID-19 disease. Despite being rare,…

A new case study reports the rare co-occurrence of cold agglutinin disease (CAD) and blood cancer in a man in Iran. The patient, 56, who had been diagnosed with myelodysplastic syndrome (MDS), an umbrella term for a group of rare blood cancers, was found to also have CAD…

A woman developed cold agglutinin disease (CAD), with high levels of cold agglutinins sustained for four months after symptom onset following a third dose of a vaccine for SARS-CoV-2, the virus that causes COVID-19, a case report from Japan. According to its authors, “the present case indicates…

Cold agglutinin disease (CAD) patients who take Enjaymo (sutimlimab-jome) long term may continue to experience disease remission after treatment discontinuation, according to a small study of three female patients. Two of the three women — all treated with Enjaymo for at least three years — showed no…

Fatigue is one of the most common symptoms of cold agglutinin disease (CAD), affecting 90% of patients, a U.S. survey found. Nearly half of people with the rare autoimmune disorder who responded to the survey, on the disease burden imposed by CAD, reported experiencing fatigue on a daily basis.

A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…

A middle-aged woman’s suddenly black fingertips and dark urine were telltale symptoms that she had developed cold agglutinin disease (CAD), according to scientists. Her case was described by a team of Japanese researchers in the study, “Black fingers and dark urine: cold agglutinin disease,”…

A 71-year-old woman with primary cold agglutinin disease (CAD) was successfully treated with the glucocorticoid prednisone, a case study reported. Its scientists noted that primary CAD typically does not respond to glucocorticoids, but in particular instances like this case, it can. The study, “A Case of Idiopathic Cold…